Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...
The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human Services to the full Senate. Shares in Moderna (NASDAQ:MRNA) and BioNTech ...
Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, Marketbeat ...
BioNTech SE is advancing its oncology strategy with investigational therapies BNT327/PM8002 and mRNA cancer immunotherapy candidates to establish a new immuno-oncology backbone targeting a variety ...
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...
BioNTech SE (“BioNTech”) confirmed the completion of its acquisition of biotechnology company Biotheus for an upfront payment ...
The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...
I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand ...
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the ...